| Dr Eugene G Brown, MD | |
|
2295 Henry Tecklenburg Dr, Charleston, SC 29414-7801 | |
| (843) 766-7103 | |
| Not Available |
| Full Name | Dr Eugene G Brown |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 29 Years |
| Location | 2295 Henry Tecklenburg Dr, Charleston, South Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245238930 | NPI | - | NPPES |
| T26576 | Medicaid | SC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 18685 (South Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Roper Hospital | Charleston, SC | Hospital |
| Musc Medical Center | Charleston, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Charleston Ent Associates, Llc | 4082662234 | 64 |
News Archive
Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for addiction and obesity, announced today that the Louisiana State University Health Sciences Center (LSUHSC-S) has received a $3.9 million dollar grant from the National Institute on Drug Abuse (NIDA). The grant will support the next stages of development for Embera's drug candidate EMB-001 to treat cocaine dependence, as well as advance EMB-001 into clinical testing.
The era of widely available next generation personal genomic testing has arrived and with it the ability to quickly and relatively affordably learn the sequence of your entire genome. This would include what is referred to as the "exome," your complete set of protein-coding sequences.
Before you swallow a tablet, or put it into a glass of water to dissolve, do you ever stop and think about how it actually works in your body and how quickly and effectively it can deliver the drug to where it is needed?
Administration of the EGLN inhibitor FG-4592 prior to ablative radiotherapy provided protection against fatal gastrointestinal bleeding and improved survival in a mouse model of unresectable pancreatic cancer.
Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that the U.S. Food and Drug Administration (FDA) has cleared for marketing its APTIMA Trichomonas vaginalis Assay on the Company's fully-automated PANTHER System.
› Verified 2 days ago
| Entity Name | Charleston Ent Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588607303 PECOS PAC ID: 4082662234 Enrollment ID: O20050105000267 |
News Archive
Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for addiction and obesity, announced today that the Louisiana State University Health Sciences Center (LSUHSC-S) has received a $3.9 million dollar grant from the National Institute on Drug Abuse (NIDA). The grant will support the next stages of development for Embera's drug candidate EMB-001 to treat cocaine dependence, as well as advance EMB-001 into clinical testing.
The era of widely available next generation personal genomic testing has arrived and with it the ability to quickly and relatively affordably learn the sequence of your entire genome. This would include what is referred to as the "exome," your complete set of protein-coding sequences.
Before you swallow a tablet, or put it into a glass of water to dissolve, do you ever stop and think about how it actually works in your body and how quickly and effectively it can deliver the drug to where it is needed?
Administration of the EGLN inhibitor FG-4592 prior to ablative radiotherapy provided protection against fatal gastrointestinal bleeding and improved survival in a mouse model of unresectable pancreatic cancer.
Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that the U.S. Food and Drug Administration (FDA) has cleared for marketing its APTIMA Trichomonas vaginalis Assay on the Company's fully-automated PANTHER System.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Eugene G Brown, MD 2295 Henry Tecklenburg Dr, Charleston, SC 29414-7801 Ph: (843) 766-7103 | Dr Eugene G Brown, MD 2295 Henry Tecklenburg Dr, Charleston, SC 29414-7801 Ph: (843) 766-7103 |
News Archive
Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for addiction and obesity, announced today that the Louisiana State University Health Sciences Center (LSUHSC-S) has received a $3.9 million dollar grant from the National Institute on Drug Abuse (NIDA). The grant will support the next stages of development for Embera's drug candidate EMB-001 to treat cocaine dependence, as well as advance EMB-001 into clinical testing.
The era of widely available next generation personal genomic testing has arrived and with it the ability to quickly and relatively affordably learn the sequence of your entire genome. This would include what is referred to as the "exome," your complete set of protein-coding sequences.
Before you swallow a tablet, or put it into a glass of water to dissolve, do you ever stop and think about how it actually works in your body and how quickly and effectively it can deliver the drug to where it is needed?
Administration of the EGLN inhibitor FG-4592 prior to ablative radiotherapy provided protection against fatal gastrointestinal bleeding and improved survival in a mouse model of unresectable pancreatic cancer.
Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that the U.S. Food and Drug Administration (FDA) has cleared for marketing its APTIMA Trichomonas vaginalis Assay on the Company's fully-automated PANTHER System.
› Verified 2 days ago
Jenna Hanner Barengo, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 169 Ashley Ave Rm 202, Charleston, SC 29425 Phone: 740-525-0170 | |
Ronald James Mcvicar, DO Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1849 Savage Rd, Charleston, SC 29407 Phone: 843-766-7103 Fax: 843-576-2692 | |
Nicole Kloosterman, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 135 Rutledge Ave # Msc550, Charleston, SC 29425 Phone: 843-792-8299 | |
Dr. Mark Drury Ghegan, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1849 Savage Rd, Charleston, SC 29407 Phone: 843-766-7103 Fax: 843-763-3834 | |
Anthony Ghanem, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 135 Rutledge Ave Ste 1130, Charleston, SC 29425 Phone: 843-876-0791 Fax: 843-792-0546 | |
Dr. David Watson Rodwell Iii, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 67 Broad St, Suite 200, Charleston, SC 29401 Phone: 843-628-1415 | |
Ted Meyer, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 171 Ashley Ave, Charleston, SC 29425 Phone: 843-792-1414 |